Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nucleic acid for the treatment of cancer: Genetic vaccines and DNA adjuvants
Autore:
Leitner, WW; Hammerl, P; Thalhamer, J;
Indirizzi:
NCI, Surg Branch, NIH, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892NCI, Surg Branch, NIH, Bethesda, MD 20892 USA Salzburg Univ, Immunol Grp, Inst Chem & Biochem, A-5020 Salzburg, Austria Salzburg Univ Salzburg Austria A-5020 Biochem, A-5020 Salzburg, Austria
Titolo Testata:
CURRENT PHARMACEUTICAL DESIGN
fascicolo: 16, volume: 7, anno: 2001,
pagine: 1641 - 1667
SICI:
1381-6128(200111)7:16<1641:NAFTTO>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYTOTOXIC-T-LYMPHOCYTE; COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; B-CELL LYMPHOMA; ANTIGEN-PRESENTING CELLS; IMMUNODEFICIENCY-VIRUS TYPE-1; MYCOBACTERIUM-BOVIS BCG; MARROW-DERIVED CELLS; TOLL-LIKE RECEPTOR-2; PLASMID DNA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
203
Recensione:
Indirizzi per estratti:
Indirizzo: Leitner, WW NCI, Surg Branch, NIH, Room 2B46,Bldg 10, Bethesda, MD 20892 USA NCI Room 2B46,Bldg 10 Bethesda MD USA 20892 esda, MD 20892 USA
Citazione:
W.W. Leitner et al., "Nucleic acid for the treatment of cancer: Genetic vaccines and DNA adjuvants", CUR PHARM D, 7(16), 2001, pp. 1641-1667

Abstract

Despite some interesting pilot experiments more than a century ago, nucleic acid has only recently been added to the list of agents used for the prevention and therapy of cancer. Two distinct features of nucleic acids are used for this purpose: in DNA and RNA vaccines, genetic information for pathogen- or tumor-derived antigens is delivered to the host who then produces the encoded antigen and initiates an immune response. In DNA adjuvants, immunostimulatory sequences (CpG motifs) present in DNA of bacterial origin areused. Such sequences are delivered in the form of oligonucleotides or within the sequence of DNA vaccine. In addition, CpG oligonucleotides by themselves have successfully been used to stimulate the immune system in an antigen-independent manner for the treatment of experimental tumors. DNA and RNAvaccines for the treatment and prevention of cancer and other diseases suffer from two some shortcomings: insufficient immunogenicity and - in the case of RNA - low stability. A variety of strategies are being explored to improve the efficacy of nucleic acid vaccines (genetic vaccines) especially for self-antigens in the case of cancer. Among the most recent improvements are self-replicating RNA vaccines and replicase-based DNA-vaccines in whichantigen expression is under the control of an alphaviral replicase. Despite highly promising results in many animal tumor models the efficacy of nucleic acid vaccines and adjuvants in the clinic remains to be seen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 22:02:14